Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan

Hsu, Hsu‐Mei; Lee, Shin-Chwen; Wang, Min-Ching; Lin, Szu-Fong; Chen, Ding‐Shinn

doi:10.1016/s0264-410x(01)00015-9

Cited by 23 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in agreement with other studies, indicating that in HBV vaccination programmes sex is not a variable that has to be considered in order to evaluate the efficacy of the campaign [1,[6][7][8]15].…”

Section: Discussionsupporting

confidence: 92%

“…This result is slightly higher compared with the findings of other studies performed in Taiwan, Turkey, The Gambia and Palestine (Gaza) that show percentages of non-responders of 3.3%, 2.3%, 5% and 5.5% respectively [6][7][8]. Further studies in the future will be needed to identify the reason for lower immune responses (pathology, ethnicity, family history, etc.).…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya

Madour¹,

Alkout²,

Vanin³

2013

East Mediterr Health J

View full text Add to dashboard Cite

The hepatitis B virus (HBV) vaccination schedule in Libya follows international recommendations (1st dose at birth, 2nd after 1 month and 3rd after 6 months). This research aimed to evaluate the long-term protection of the HBV immunization programme in Tripoli and to determine the best age to administer booster doses. Serum levels of hepatitis B surface antigen were determined in 277 randomly selected children aged 1-12 years. The response to HBV vaccine in 1-3-year-olds was 93.2%, but this declined with age and at 7-9 years after initial vaccination only 53.1% of children had protective titres (≥ 10 mIU/mL). No significant differences between males and females in antibody persistence or response to vaccine were observed. We recommend continuing the HBV vaccination programme and that a booster dose be given to 6-year-old children to ensure maximum protection during the period of school entry and beyond.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 55%

First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya

Madour¹,

Alkout²,

Vanin³

2013

East Mediterr Health J

View full text Add to dashboard Cite

show abstract

“…The mutation was found in natural isolates, and immune pressure upon vaccination favours its selection. In countries with mass vaccination programmes, for example Taiwan [113], a substantial increase in HBs escape variants of up to 28% has been documented, concurrent with a 10-fold decrease in the HBs carrier rate in children [114]. Generally, escape mutations were found mainly in the aa 139-147 loop, or HBs4 region of the a determinant, predominantly at position 145 (G145R) [115].…”

Section: Vaccine-induced Mutationsmentioning

confidence: 99%

Molecular Epidemiology and Immunology of Hepatitis B Virus Infection – An Update

2002

View full text Add to dashboard Cite

Hepatitis B virus (HBV) continues to be one of the most important viral pathogens in humans. This review provides an update on the molecular epidemiology and immunology of HBV infection. DNA sequencing has allowed replacement of the initial serotypic classification of HBV strains by a more systematic genotype system that currently consists of 7 members (genotypes A–G). More recently, sequence analysis of virus isolates from many individual patients has revealed the occurrence of certain mutational hot spots in the genome, some of which appear to correlate with the patient’s immunological and/or disease status; however, cause and effect are not always easily discernible. This holds particularly for the issue of whether virus variants exist that have, per se, an increased pathogenic potential; due to the scarcity of appropriate experimental in vivo models, such hypotheses are difficult to prove. Similarly, because of the compact organization of the HBV genome, almost every single mutation may have pleiotropic phenotypic effects. Nonetheless, there is accumulating evidence that at least some frequently observed mutations are causally related to viral escape from selective pressures, such as the presence of antibodies against dominant B cell epitopes, or drugs that inhibit the viral reverse transcriptase; possibly, this is also true for the cellular immune response. Therefore, despite the availability of an effective prophylactic vaccine, further extensive efforts are required to monitor the emergence of vaccination- and therapy-resistant HBV variants and to prevent their spread in the general population.

show abstract

“…Since post-exposure prophylaxis with both HepB and HBIG is more effective compared with HepB alone for prevention of perinatal HBV transmission, 3 continued efforts to support maternal HBsAg screening and HBIG coverage are needed. 6,7 HBsAg testing free of charge might improve the rates of screening among pregnant women, cost-effectiveness studies are needed to evaluate.…”

Section: Discussionmentioning

confidence: 99%

“…[3][4][5] Studies in areas highly endemic for HBV have shown that passive-active PEP with HBIG and HepB more effectively prevents perinatal HBV transmission than HepB alone. [6][7][8] The World Health Organization (WHO) recommends universal HepB as soon as possible after birth, preferably within 24 h regardless of maternal HBsAg status, even in countries with low-endemicity. 9 In the United Sates, the Advisory Committee on Immunization Practices (ACIP) recommends infants born to HBsAg-positive mothers receive HepB and HBIG within 12 h of birth, and HepB before hospital discharge for infants of mothers with known HBsAg-negative status.…”

Section: Introductionmentioning

confidence: 99%

Perinatal hepatitis B prevention program in Shandong Province, China

Zhang

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan

Cited by 23 publications

References 17 publications

First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya

First evaluation of the serum level of anti-hepatitis B surface antigen after vaccination in Libya

Molecular Epidemiology and Immunology of Hepatitis B Virus Infection – An Update

Perinatal hepatitis B prevention program in Shandong Province, China

Contact Info

Product

Resources

About